700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Insmed Reports Q3 2025 Results, BRINSUPRI™ Approved by FDA
Investor Presentation
Financial Results, Press Release
Announces Pricing of $750 Million Public Offering of Common Stock
Reg. FD, Other Events
Other Events
Material disclosure
Earnings Release
Q3
Q2
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus